Exclusive: Biogen leaders warn sales teams: Only 2,000 patients might access Aduhelm over the next several years

Biogen execs on Thursday tried to level with their Aduhelm sales staff and prep for a 28-day blitz to convince CMS to reverse or loosen its recent decision to only cover the controversial Alzheimer’s drug in clinical trials.

Its back against the wall, the company faces an Aduhelm launch that never materialized and growing ire from investors as they try to generate some of the glittering billions in blockbuster sales analysts once so confidently forecast.

According to a recording of the Zoom call with sales teams, obtained by Endpoints News, Brendan Manquin, VP of US market access and reimbursement at Biogen, slammed the implications of the draft NCD, and said it means that even if Biogen runs a large, randomized placebo-controlled Phase III trial, on the order of 2,000 to 3,000 patients (with 33-50% on placebo), that means only about 1,000 to 2,000 patients will access Aduhelm “over the…
Click here to view original post